Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT06339411

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06339411
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06339411. Randomized; triple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy
Acronym
CARE-EVT
Condition
Acute Ischemic Stroke
Intervention (Drug)
Cerebrolysin
Intervention (Drug)
Normal saline placebo
Lead sponsor
Chang Gung Memorial Hospital (class: other)
Collaborator
EVER Pharma France SAS (class: not stated)

Record details

Record id
cardio:ct-nct06339411
Content hash
f5109981fe80e8707430b24f05a63fa760113a4a0ee5991d84250370e00fd7df